Tirzepatide Protocol
Dosing & Research
Last Updated: April 22, 2026
Diabetes and obesity research, GIP/GLP-1 dual agonist pharmacology, Weight-loss outcomes, Cardiometabolic studies
Evidence Level
Human Clinical Data Available
Species Studied
Human • Rat • Mouse
Half-Life
~5 Days
Administration
Subcutaneous
Frequency
Once Or Twice Weekly, Same Day(s) Each Week
How It Works
- Diabetes and obesity research
- GIP/GLP-1 dual agonist pharmacology
- Weight-loss outcomes
- Cardiometabolic studies
Dosing Structure
Dose
2.5–5.0 mg weekly (up to 7.5 mg)
Frequency
Once Or Twice Weekly, Same Day(s) Each Week
Notes
1x Weekly titration: Week 1-4: 2.5mg | Week 5-8: 5mg | Week 9-12: 7.5mg | Week 13-16: 10mg | Week 17-20: 12.5mg | Week 21+: 15mg. 2x Weekly titration: Week 1-4: 1.25mg | Week 5-8: 2.5mg | Week 9-12: 3.75mg | Week 13-16: 5mg | Week 17-20: 6.25mg | Week 21+: 7.5mg. No need to increase dose if experiencing benefits. Inject: Thigh, abdomen (2+ inches from navel), upper arm. Any time of day, with or without food. Medical supervision required for discontinuation. Typically follows a weekly titration schedule.
Example Protocols
Dose: 2.5–5.0 mg weekly (up to 7.5 mg)
Frequency: Once Or Twice Weekly, Same Day(s) Each Week
Duration: 8-48 weeks
Off Period: Not listed
Protocol Notes
1x Weekly titration
Week 1-4: 2.5mgWeek 5-8: 5mgWeek 9-12: 7.5mgWeek 13-16: 10mgWeek 17-20: 12.5mgWeek 21+: 15mg
2x Weekly titration
Week 1-4: 1.25mgWeek 5-8: 2.5mgWeek 9-12: 3.75mgWeek 13-16: 5mgWeek 17-20: 6.25mgWeek 21+: 7.5mg
•
No need to increase dose if experiencing benefits.
•
Inject: Thigh, abdomen (2+ inches from navel), upper arm.
•
Any time of day, with or without food.
•
Medical supervision required for discontinuation.
•
Typically follows a weekly titration schedule.
Research & Studies
Loading citations…
- Curated References
- CuratedPubMedPMID 35658024Tirzepatide Once Weekly for the Treatment of Obesity↗N Engl J Med · 2022 · Jastreboff AM, Aronne LJ, Ahmad NN, et al.dosingefficacyobesityphase-3
- CuratedPubMedPMID 34170647Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes↗N Engl J Med · 2021 · Frias JP, Davies MJ, Rosenstock J, et al.dosingT2Dphase-3comparative
- CuratedPubMedPMID 37210472Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis↗N Engl J Med · 2023 · Loomba R, Hartman ML, Lawitz EJ, et al.MASHliverphase-2
- CuratedPubMedPMID 37952191Tirzepatide for the Treatment of Obesity: Rationale and Design of the SURMOUNT Clinical Development Program↗Obesity · 2023 · Wadden TA, et al.dosingobesityphase-3
Research Feedback
0 approved
For research discussion only. Community feedback is moderated and shown here as aggregated insights after approval.
Be the first to submit research feedback for this peptide.
Approved submissions will appear here as aggregated insights.